BC­MA ri­val to blue­bird, Bris­tol My­ers files for $100M IPO as the fron­trun­ners stum­ble in a race to the fin­ish line

On the same day that blue­bird and Bris­tol My­ers had to try and ex­plain to an­a­lysts why their cru­cial ap­pli­ca­tion for the BC­MA drug ide-cel (bb2121) was kicked back by the FDA in a sting­ing refuse-to-file no­tice, a top con­tender for leapfrog­ging them to the mar­ket was lay­ing out a $100 mil­lion IPO and de­tails of the rich, $1.7 bil­lion deal with J&J that has been greas­ing the tracks of R&D and man­u­fac­tur­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.